Clinical trial
BI 655066/ABBV-066 (Risankizumab) Versus Ustekinumab and Placebo Comparators in a Randomized Double Blind trIal for Maintenance Use in Moderate to Severe Plaque Type Psoriasis (UltIMMa-1)
This is a randomized double blind, double dummy, placebo and active comparator controlled, parallel design study that is being performed to assess the safety and efficacy of BI 655066/ABBV-066 (risankizumab) to support registration for the treatment of moderate to severe chronic plaque psoriasis in adult patients.
| Category | Value |
|---|---|
| Date last updated at source | 2017-01-31 |
| Study type(s) | Interventional |
| Expected enrolment | 500 |
| Study start date | 2016-02-01 |
| Estimated primary completion date | 2017-09-01 |